Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emmaus Medical has entered into an exclusive sublicense agreement with Cato BioVentures of Research Triangle Park, for the patent protected drug NutreStore brand L-Glutamine.
Subscribe to our email newsletter
Under this agreement, Emmaus will commercialize NutreStore, which is approved by the FDA for use in combination with human growth hormone as a treatment for short bowel syndrome (SBS). Emmaus will be introducing NutreStore in the spring of 2008 and projects that its sales will greatly contribute to its short and long term financial performance of the company.
Joel Eisner, associate principal of Cato BioVentures, said: “Cato BioVentures is excited to partner with Emmaus Medical for the marketing of NutreStore and looks forward to a long and successful relationship with the company.”